Id: acc3767
Group: 1sens
Protein: P70S6K
Gene Symbol: RPS6KB1
Protein Id: P23443
Protein Name: KS6B1_HUMAN
PTM: phosphorylation
Site: Ser411
Site Sequence: ESANQVFLGFTYVAPSVLESV
Disease Category: Cancer
Disease: Sarcoma
Disease Subtype: Kaposi sarcoma
Disease Cellline:
Disease Info:
Drug: rapamycin
Drug Info: Rapamycin is a macrolide compound that is used as an immunosuppressant and has potential applications in treating various diseases such as cancer and aging-related conditions.
Effect: modulate
Effect Info: "After long-term treatment with rapamycin, the phosphorylation of AKT and P70 (S6K) was significantly inhibited, accompanied by the regression of skin tumors."
Note:
Score: 4.0
Pubmed(PMID): 17336708
Sentence Index:
Sentence:

Sequence & Structure:

MRRRRRRDGFYPAPDFRDREAEDMAGVFDIDLDQPEDAGSEDELEEGGQLNESMDHGGVGPYELGMEHCEKFEISETSVNRGPEKIRPECFELLRVLGKGGYGKVFQVRKVTGANTGKIFAMKVLKKAMIVRNAKDTAHTKAERNILEEVKHPFIVDLIYAFQTGGKLYLILEYLSGGELFMQLEREGIFMEDTACFYLAEISMALGHLHQKGIIYRDLKPENIMLNHQGHVKLTDFGLCKESIHDGTVTHTFCGTIEYMAPEILMRSGHNRAVDWWSLGALMYDMLTGAPPFTGENRKKTIDKILKCKLNLPPYLTQEARDLLKKLLKRNAASRLGAGPGDAGEVQAHPFFRHINWEELLARKVEPPFKPLLQSEEDVSQFDSKFTRQTPVDSPDDSTLSESANQVFLGFTYVAPSVLESVKEKFSFEPKIRSPRRFIGSPRTPVSPVKFSPGDFWGRGASASTANPQTPVEYPMETSGIEQMDVTMSGEASAPLPIRQPNSGPYKKQAFPMISKRPEHLRMNL

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
RPS6KB1 TAS0612 Ribosomal protein S6 kinase (P70S6K) inhibitor 1 Recruiting neoplasm ClinicalTrials
RPS6KB1 MSC-2363318A Ribosomal protein S6 kinase (P70S6K) inhibitor 1 Completed neoplasm ClinicalTrials
RPS6KB1 LY-2780301 Ribosomal protein S6 kinase (P70S6K) inhibitor 1 Completed lymphoma ClinicalTrials
RPS6KB1 XL-418 Ribosomal protein S6 kinase (P70S6K) inhibitor 1 Suspended neoplasm ClinicalTrials
RPS6KB1 LY-2584702 Ribosomal protein S6 kinase 1 inhibitor 1 Terminated renal cell carcinoma ClinicalTrials
RPS6KB1 LY-2584702 Ribosomal protein S6 kinase 1 inhibitor 1 Terminated non-small cell lung carcinoma ClinicalTrials
RPS6KB1 LY-2584702 Ribosomal protein S6 kinase 1 inhibitor 1 Terminated metastasis ClinicalTrials
RPS6KB1 LY-2780301 Ribosomal protein S6 kinase (P70S6K) inhibitor 1 Completed metastasis ClinicalTrials
RPS6KB1 LY-2584702 Ribosomal protein S6 kinase 1 inhibitor 1 Terminated neuroendocrine neoplasm ClinicalTrials
RPS6KB1 LY-2584702 Ribosomal protein S6 kinase 1 inhibitor 1 Completed cancer ClinicalTrials
RPS6KB1 LY-2584702 Ribosomal protein S6 kinase 1 inhibitor 1 Terminated cancer ClinicalTrials
RPS6KB1 XL-418 Ribosomal protein S6 kinase (P70S6K) inhibitor 1 Suspended cancer ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC
RPS6KB1-Ser411
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
S 394 D Head and neck squamous cell carcinoma Phosphorylation 21281788
S 418 D Pancreatic ductal adenocarcinoma Phosphorylation 27014871
T 412 D Head and neck squamous cell carcinoma Phosphorylation 21281788
T 389 P Liver cancer Phosphorylation 23537100
- - P Ameloblastoma Phosphorylation 22977662
- - U Breast cancer/tumor/carcinoma Phosphorylation 23794518
S 371 U Pancreatic ductal adenocarcinoma Phosphorylation 27014871
- - U Osteogenic sarcoma/osteosarcoma Phosphorylation 23879172
- - U Non-small cell lung cancer/carcinoma Phosphorylation 23886172
- - U Gallbladder cancer Phosphorylation 24124380
- - U Breast cancer/tumor/carcinoma Phosphorylation 24023352
- - U Hepatocellular carcinoma/hepatocarcinoma/hepatoma Phosphorylation 23934262
- - U Lung adenocarcinoma Phosphorylation 23934262
- - U Chronic myelogenous leukemia/chronic myeloid leukemia Phosphorylation 23384908
T 412 U Diabetes mellitus Phosphorylation 35835217
T 412 U Hypertrophic cardiomyopathy Phosphorylation 20190034
T 424 U Alzheimer's disease Phosphorylation 16364302
T 421 U Pancreatic ductal adenocarcinoma Phosphorylation 27014871
T 421 U Alzheimer's disease Phosphorylation 16364302
T 412 U Thyroid cancer Phosphorylation 36195659
T 412 U Rheumatoid arthritis Phosphorylation 35015571
T 412 U Ovarian cancer/carcinoma Phosphorylation 21276607

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: